Why McKesson (MCK) is Back on Investors’ Radar Recent quarterly results from McKesson (MCK), with revenue and operating profit ahead of expectations, have turned the stock into a focal point for many ...
McKesson (MCK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
McKesson Corporation is rated a Hold due to low debt burden and faces risks from regulatory and margin pressures. Learn more ...
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
McKesson (MCK), a prominent pharmaceutical wholesaler, experienced a stock increase of 17% during a high-volume trading session.
IRVING, Texas – McKesson is moving steadily toward taking its Medical-Surgical business public in the second half of calendar year 2027, CEO and Director Brian Tyler said on a recent earnings call.
The healthcare workforce management system market is expanding rapidly, driven by digital HR adoption, AI-driven workforce ...
Ending months of speculation, McKesson opted last month to separate its IT business so that it could focus its resources on its growing drug distribution business. Under a plan outlined last June, ...
McKesson Corporation stock reached an all-time high of 972.06 USD, marking a significant milestone for the company. Currently trading at $971.22 with a market capitalization of $118.86 billion, the ...
McKesson Corporation is a major pharmaceutical distributor that offers health care supply chain management, retail pharmacy, oncology, specialty care and health care information technology services.
McKesson is expanding its footprint in the oncology field with a combined $1.2 billion acquisition of two companies – Vantage Oncology and Biologics. Vantage Oncology provides radiation oncology, ...
McKesson is a relatively stable and safe investment that give investors exposure to the healthcare industry. Although sales haven't been skyrocketing, the company's top line has been moving in the ...